Department of Medical Oncology and Neurological Sciences of Azienda Ospedale-Università, Padua, Italy
Received 21 April 2003; revised 8 July 2003; accepted 12 August 2003
![]() |
Abstract |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
This study was a phase II study of third-line chemotherapy with carboplatin plus teniposide in patients with recurrent oligodendroglioma.
Patients and methods:
Patients with oligodendroglioma progressive or recurrent after surgery, radiotherapy and chemotherapy with PCV (lomustine/procarbazine/vincristine) and temozolomide were treated with 350 mg/m2 carboplatin on day 1, and 50 mg/m2 teniposide on days 13, every 4 weeks.
Results:
Response and toxicity were evaluated in all 23 patients enrolled in the study. Two had partial response [8.6%; 95% confidence interval (CI) 1.8% to 28.6%] and 12 stable disease (52.17%; 95% CI 30% to 73%). Median time to progression was 19 weeks (95% CI 11.435.0), and 34.8% of the patients (95% CI 20.0% to 61.0%) had progression-free survival at 6 months. Median survival time was 60.7 weeks (95% CI 39.8 to not achieved) and 51% of the patients (95% CI 33.5% to 79.7%) were alive at 12 months. A total of 103 cycles were administered (on average 4.4 per patient; range 19). Toxicity was mild and mainly hematological, with grade 4 neutropenia and grade 4 thrombocytopenia in two (8.6%) and three patients (13%), respectively.
Conclusions:
Although the response rate of combined carboplatin and teniposide chemotherapy in heavily pretreated oligodendroglial tumors is moderate, the toxicity is manageable, and delay of progression in responders or stable patients may still confer a relevant clinical benefit.
Key words: carboplatin, chemotherapy, oligodendroglioma, salvage therapy, teniposide
![]() |
Introduction |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
A phase II study of carboplatin plus teniposide was thus planned at our institution in order to evaluate tumor control rate and toxicity of this association in oligodendroglioma patients recurring after both nitrosoureas and temozolomide.
![]() |
Patients and methods |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Treatment plan
Carboplatin 350 mg/m2 and teniposide 50 mg/m2 were administered intravenously on day 1 and on days 13, respectively. The treatment was repeated every 4 weeks, for a maximum of 10 cycles. The patients were evaluated weekly for hematological toxicity, and monthly for renal and hepatic toxicity, which was recorded according to World Health Organization criteria [13]. Carboplatin and teniposide were reduced by 75% if hematological toxicity was grade 4 at nadir. Treatment was suspended if bone marrow recovery was unsatisfactory after 1 month, or in the presence of extra-hematological toxicity grade 3.
Prophylactic 5-hydroxytryptamine type 3 receptor antagonists were routinely used. Steroids were administered at the lowest dosage required by the patients neurological status, and any increase due to clinical deterioration was considered in the evaluation of response. All patients received antiepileptic drugs, the plasma concentrations of which were checked several times during treatment in view of possible hepatic metabolism interference induced by chemotherapy [14].
Response evaluation
All response evaluations were carried out by a multidisciplinary team consisting of a neuroradiologist, oncologist, neurosurgeon and radiotherapist. According to Macdonalds criteria [15], tumor size was considered the maximum cross-sectional area of the enhancing mass at CT (post-iodinated contrast) or MRI (T1-weighted, post-gadolinium) and calculated by multiplying the largest cross-sectional dimension (cm) by the largest dimension perpendicular to it.
Complete response (CR) was defined as the disappearance of all tumors with contrast enhancement on two consecutive imaging studies taken at least 1 month apart, with the patient off steroids, and when his/her neurological status was stable or had improved.
Partial response (PR) was considered a 50% reduction in the size of the enhancing tumor on two consecutive imaging studies taken at least 1 month apart, with a stable or reduced steroid dose, and when the patients neurological status was stable or had improved.
Disease was considered progressive disease (PD) if there was a 25% increase in the size of the enhancing tumor, any new tumor was found at CT/MRI scan, the patients neurological condition had deteriorated and/or the steroid dose was stable or had increased. All other conditions were considered stable disease (SD).
A clinical assessment and a CT scan or MRI of the brain with and without contrast were carried out before enrollment and after every two courses of treatment.
Objectives
The main objective was to evaluate the RR (CR plus PR) of carboplatin plus teniposide chemotherapy in recurrent oligodendroglioma. Secondary objectives were: toxicity, TTP (time interval from the start of chemotherapy to progression of disease or exit from the study for any reason), PFS-6 (progression-free survival at 6 months) and MST (median time interval from the start of chemotherapy to death from any cause).
Statistical methods
The trial was designed as a phase II study, with RR as the main end point. According to Simons two-stage optimal design [16], our study with its sample size of n = 72, had a 5% probability of rejecting () the hypothesis of an RR <20% and an 80% probability of accepting (1ß) the hypothesis of an RR of 35%.
During the first stage, if fewer than five responses are obtained among the initial 22 patients, it would be concluded that the RR is <20%, and the study would be terminated.
Patients who received at least two cycles of treatment were considered assessable for response unless they had definite evidence of progression after the first cycle, otherwise they were considered assessable only for toxicity.
TTP, PFS-6 and MST were calculated with the KaplanMeier method; differences in progression and overall survival were evaluated by the log-rank test for statistical significance. To determine truly independent variables, the Cox model of multivariate analysis was applied to variables with P <0.05 on univariate analysis. Age (50 or <50 years), KPS (
70 or <70), presence or absence of an astrocytic component, time between first surgery or the end of radiotherapy and start of carboplatin plus etoposide chemotherapy (
12 months or <12 months), response to previous PCV and/or previous temozolomide were considered variables connected to TTP and MST.
The Wilcoxon and MannWhitney U-tests were used for the analysis of the non-parametric variables within and between groups (i.e. KPS). The McNemar 2 test was used to determine the significance of changes when the variables of interest were dichotomous.
![]() |
Results |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
|
Response to treatment
We observed two PRs [8.6%; 95% confidence interval (CI) 1.8% to 28.6%], and 12 SDs (52.17%; 95% CI 30% to 73%). Both PRs and six SDs were achieved by patients who had low-grade tumors at the latest surgery. Seventy per cent of patients with pure oligodendroglioma and 33.3% of those with mixed oligoastrocytoma remained progression-free during chemotherapy. The change in median KPS value in patients with tumor response or stabilization of disease was significantly different from that observed in patients with disease progression (P = 0.02, MannWhitney U-test): the former group showed a significant improvement in KPS with respect to the baseline (76.479.3) (P = 0.05, Wilcoxon test), whereas the latter group showed a statistically significant worsening in KPS (75.566.7) (P = 0.04, Wilcoxon test). A significant correlation (P <0.01, McNemar test) was found between response or stabilization obtained with carboplatin and teniposide and response or stabilization previously obtained with PCV chemotherapy. Multivariate analysis showed that histology was a true independent prognostic factor (P <0.01).
Time to progression
Considering all 23 patients, median TTP was 19 weeks (95% CI 11.435.0); PFS-6 was 34.8% (95% CI 20.0% to 61.0%) (Table 2). The patients with response or stabilization had a TTP of 28 weeks (95% CI 16.460.7) and PFS-6 of 57% (95% CI 36.3% to 90.0%). Patients with pure oligodendroglioma had a significantly (P = 0.04) longer TTP and PFS-6 (TTP = 25 weeks, 95% CI 649.3; PFS-6 = 47%, 95% CI 28.0% to 78.0%) than those with oligoastrocytoma [TTP = 6 weeks, 95% CI 1.7 to not achieved (NA); PFS-6 = 0%].
|
The patients with response or stabilization obtained a significantly (P = 0.005) higher MST (98.3 weeks, 95% CI 60.7NA), with 74.6% (95% CI 53.0% to 100%) of patients alive at 12 months, compared with patients with PD (MST = 23.4 weeks, 95% CI 7.4NA, of whom none was alive at 12 months). The patients with pure oligodendroglioma had a significantly (P = 0.002) longer MST (98.3 weeks, 95% CI 60.7NA), with 71% (95% CI 50.5% to 100%) of patients alive at 12 months, than those with oligoastrocytoma (MST = 15.4 weeks, 95% CI 1.7NA; no patients alive at 12 months). The patients with low-grade oligodendroglioma at the most recent surgery had a significantly (P = 0.04) longer MST (98.3 weeks, 95% CI 98.3NA), with 79% (95% CI 56.4% to 100%) of patients alive at 12 months, than those with high-grade tumors (MST = 43.14 weeks, 95% CI 23.4NA; with 37% (95% CI 17.8% to 76.8%) alive at 12 months. No other variables were found to be significantly correlated with survival.
At multivariate analysis the only true independent predictive variables were histology (P = 0.003) and response to this chemotherapy regimen (P = 0.005).
Toxicity
All patients were assessable for toxicity. A total of 103 cycles were administered (on average, 4.4 per patient; range 19). Treatment-related complications included grade 3 thrombocytopenia in two patients (8.6%) and grade 4 thrombocytopenia in three (13.0%), and grade 3 neutropenia in two (8.6%) and grade 4 neutropenia in two patients (8.6%). Two patients required a 25% reduction in chemotherapy doses due to hematological toxicity; no patients required cytokine therapy for myelosuppression, and there were no treatment-related deaths.
![]() |
Discussion |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Friedman et al. [7] reported 88% of disease stabilization (in eight of nine chemonaive patients) and suggested that further studies should be undertaken to establish whether carboplatin might replace PCV chemotherapy in view of its better tolerability.
With regard to other salvage therapy regimens employed, Chamberlain and Kormanik [18] studied paclitaxel in 20 oligodendroglioma patients recurrent after radiotherapy and PCV: three patients achieved a PR (15%) and seven an SD (35%) with a median response and SD duration of 10 months (range 514).
Carboplatin and teniposide achieved a very modest objective RR in our oligodendroglioma patients, but it is important to bear in mind that this approach was used as a third-line therapy. Nine patients had low-grade tumors without contrast enhancement at the latest surgery, but all of these patients had had disease progression after radiotherapy and two lines of chemotherapy, and had contrast-enhancing, inoperable tumors for which repeat biopsy was not performed because the tumors were known to be malignant. In the setting of palliative chemotherapy, 52% disease stabilization lasting >28 weeks, with 57% of patients without disease progression at 6 months, and with a significant improvement in KPS, are results of appreciable clinical relevance. This regimen should be considered especially for patients with pure oligodendroglioma who have responded to first-line chemotherapy. In fact, the absence of an astrocytic component, and a response to previous chemotherapy, were statistically correlated in multivariate analysis with RR, TTP and survival.
The close correlation between pure oligodendroglial histology, TTP and MST was reported by Kim et al. [19] in their study on PCV as first-line chemotherapy: patients with oligodendroglioma versus oligoastrocytoma grade III achieved a median TTP of 63.4 compared with 13.8 months (P = 0.03) and a MST of 76 months compared with 49.8 months (P = 0.01).
Smith et al. [20] reported that the chemosensitivity of a subset of oligodendrogliomas was associated with alterations of chromosome arms 1p and 19q. In our population there was a strict correlation between response to PCV and/or temozolomide and disease stabilization with the present regimen, possibly indicating that some genetic alterations conferring chemosensitivity could maintain their relevance even in advanced disease.
In our study, carboplatin and teniposide chemotherapy did not cause any significant morbidity, with 50% of the patients receiving on average six cycles of treatment. Patients were easily treated in an outpatient setting. The mild toxicity in this heavily pretreated population may possibly be due to an increased teniposide clearance with concomitant anticonvulsant therapy [14, 21]. However, clinical evidence regarding the benefit of dose intensity in oligodendroglioma with respect to tumor response and patients survival is not compelling [22, 23].
In conclusion, the benefit of carboplatin and teniposide when used as a third-line regimen in patients with recurrent oligodendroglioma is marginal in terms of tumor response, but is not negligible in terms of stabilization of disease, which is frequently accompanied by a clinically relevant increase in both KPS and quality of life. Even in these highly pretreated patients, chemosensitivity appears to be a predictable phenomenon, and it is governed by the presence of a pure oligodendroglial histology and responsiveness to previous cytotoxic agents.
![]() |
Acknowledgement |
---|
![]() |
Footnotes |
---|
![]() |
References |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
2. Cairncross G, Macdonald D, Ludwin S et al. Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1994; 10: 20132021.
3. van den Bent MJ, Kros JM, Heimans JJ et al. Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology 1998; 4: 11401145.
4. van den Bent MJ, Keime-Guibert F, Brandes AA et al. Temozolomide chemotherapy in recurrent oligodendroglioma. Neurology 2001; 2: 340342.
5. Chinot OL, Honore S, Dufour H et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. J Clin Oncol 2000; 19: 24492455.[ISI]
6. Yung WK, Mechtler L, Gleason MJ. Intravenous carboplatin for recurrent malignant glioma: a phase II study. J Clin Oncol 1991; 9: 860864.[Abstract]
7. Friedman HS, Lovel S, Rasheed K. Treatment of adults with progressive oligodendroglioma with carboplatin: preliminary results. Med Ped Oncol 1998; 31: 1618.[CrossRef][ISI][Medline]
8. Durand RE, Goldie JH. Interaction of etoposide and cisplatin in an in vitro tumor model. Cancer Treat Rep 1987; 71: 673679.[ISI][Medline]
9. Spremulli E, Schulz JJ, Speckart VJ. Phase II study of VM-26 in adult malignancies. Cancer Treat Rep 1980; 64: 147150.[ISI][Medline]
10. Brandes AA, Rigon A, Zampieri P et al. Carboplatin and teniposide concurrent with radiotherapy in patients with glioblastoma multiforme: a phase II study. Cancer 1998; 82: 355361.[CrossRef][ISI][Medline]
11. Jeremic B, Grujicic D, Jevremovic S et al. Carboplatin and etoposide chemotherapy regimen for recurrent malignant glioma: a phase II study. J Clin Oncol 1992; 10: 10741077.[Abstract]
12. Kleihues P, Louis DN, Scheithauer BW et al. WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 2002; 3: 215225.
13. World Health Organization. WHO Handbook for reporting results of cancer treatment (WHO offset Publications no. 48). Neoplasma 1980; 20: 3746.
14. Baker DK, Relling MV, Pui CH. Increased teniposide clearance with concomitant anticonvulsant therapy. J Clin Oncol 1992; 10: 311315.[Abstract]
15. Macdonald DR, Cascino TL, Clifford S et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990; 8: 12771280.[Abstract]
16. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 110.[ISI][Medline]
17. Peterson K, Paleologos N, Forsyth P. Salvage chemotherapy for anaplastic oligodendrogliomas. J Neurosurg 1996; 85: 597601.[ISI][Medline]
18. Chamberlain MC, Kormanik PA. Salvage chemotherapy with paclitaxel for recurrent oligodendroglioma. J Clin Oncol 1997; 15: 34273432.[Abstract]
19. Kim L, Hochberg FH, Thornton AF et al. Procarbazine, lomustine, and vincristine (PCV) chemotherapy for grade III and grade IV oligoastrocytomas. J Neurosurg 1996; 4: 602607.
20. Smith JS, Perry A, Borell TJ et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas and mixed oligoastrocytomas. J Clin Oncol 2000; 18: 636645.
21. Grossman SA, Hochberg F, Fisher J et al. Increased 9-aminocamptothecin dose requirements in patients on anticonvulsants. NABTT CNS Consortium. The New Approaches to Brain Tumor Therapy. Cancer Chemother Pharmacol 1998; 2: 118126.[CrossRef]
22. Jakacki RI, Siffert J, Jamison C et al. Dose-intensive, time-compressed procarbazine, CCNU, vincristine (PCV) with peripheral blood stem cell support and concurrent radiation in patients with newly diagnosed high-grade gliomas. J Neurooncol 1999; 1: 7783.
23. Cairncross G, Swinnen L, Bayer R et al. Myeloablative chemotherapy for recurrent aggressive oligodendroglioma. Oligodendroglioma Study Group. Neuro-oncol 2000; 2: 114119.[ISI][Medline]